Methanobrevibacter Smithii Test

Methanobrevibacter smithii (M. smithii) is the dominant archaeon in the human gut. Archaea are single-celled microorganisms distinct from bacteria. M. smithii performs methanogenesis, a process that uses hydrogen gas and carbon dioxide to produce methane. By consuming hydrogen (H₂) released by neighboring microbes during fiber fermentation, M. smithii lowers hydrogen levels in the colon. This shifts the entire fermentation economy: lower hydrogen can favor continued breakdown of carbohydrates, increasing energy extraction from food. It also redirects which short-chain fatty acids are produced; studies show that high methanogenesis can reduce butyrate production in some contexts and alter the competitive fitness of key butyrate-producing bacteria. Butyrate is a short-chain fatty acid that fuels colon cells and supports an anti-inflammatory gut environment, so this trade-off matters.

These hydrogen-scavenging and cross-feeding relationships are called syntrophy, meaning partners feed each other’s metabolism. M. smithii forms syntrophic ties with species like Bacteroides and Christensenellaceae, which can increase the efficiency of energy harvest from indigestible carbohydrates. In people, higher M. smithii abundance is associated with greater energy extraction and, in some studies, weight gain. Paradoxically, it is also enriched in anorexia nervosa, likely as an adaptive response to maximize energy capture when intake is low. Clinically, methane produced by M. smithii is linked to slower intestinal transit. People with constipation-predominant irritable bowel syndrome (IBS-C) more often show methane on breath tests, while inflammatory bowel disease, short bowel syndrome, and states after renal transplantation tend to show lower methanogen colonization.

Prevalence is high worldwide but varies with diet, geography, urbanization, and antibiotic exposure. Recent work reveals at least two related clades in the human gut archaeome, M. smithii and Candidatus M. intestini, with distinct genomic features and ecological niches, which may explain variable clinical associations across studies.

Where this biomarker adds value: traditional stool reports focus on bacterial composition and short-chain fatty acids. Including M. smithii offers an additional systems-level signal about hydrogen balance, fermentation efficiency, constipation risk, and potential trade-offs with butyrate production. In a longevity or metabolic program, its trajectory over time (especially alongside fiber intake, stool form, and breath methane) can reveal whether your gut ecosystem is trending toward efficient butyrate-rich fermentation or toward hydrogen-limited, methane-dominant states that slow transit and may increase energy harvest.